Gauzy Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

Gauzy received a Nasdaq delisting notice after failing to restore its share price above $1 by the September 14, 2026 compliance deadline and failing to file its 2025 Form 20-F. The company will request a Nasdaq Hearings Panel appeal by September 22, which will keep GAUZ listed and tradeable pending the hearing, but there is no assurance the appeal will preserve its listing. The notice adds to material financial-risk concerns, including French insolvency proceedings, funding needs, continuing losses and debt-related constraints.

Analysis

GAUZ now has two independent gates to preserving exchange access: a listing-price remedy and restoration of current financial disclosure. The hearing stay creates a tradable window, not a solvency solution; absent audited filings, investors cannot validate the claimed liquidity improvement, quantify debt maturities, or assess the recovery value of the French operations. That uncertainty should sustain a steep liquidity and governance discount even if the shares avoid immediate suspension.

The most material second-order risk is financing. A sub-$1 issuer with unresolved reporting and restructuring issues has limited access to conventional equity, so any capital raise is more likely to be highly dilutive, structured, or accompanied by a reverse split. A reverse split can technically cure the bid-price test but does not resolve the disclosure deficiency or cash burn; comparable distressed microcaps often face renewed selling once post-split shares become borrowable and investors reassess the enlarged effective float.

Near term, the September 22 appeal filing is largely procedural and should not be treated as a positive catalyst. Over the next 1-3 months, the only thesis-changing evidence would be a filed 20-F containing a credible going-concern analysis, quantified liquidity runway, and a funded resolution for the French reorganization. On a 6-18 month view, customer qualification cycles in aerospace and auto are too long to offset near-term restructuring, funding, and execution risk.

Contrarian upside is possible if a strategic buyer, creditor-led recapitalization, or asset sale establishes value materially above the trading price; the appeal stay can amplify such a squeeze in a thin float. But that is an event-driven optionality trade, not support for a fundamental long. The bearish thesis is falsified only by timely audited reporting, sufficient committed capital to cover at least 12 months of operations, and an exchange-approved path addressing both deficiencies.

Key Decisions for Investors

• Avoid initiating a fundamental long in GAUZ during the appeal stay; reassess only after the 20-F is filed and cash runway, debt terms, and French restructuring obligations can be independently modeled.
• For mandates able to borrow distressed microcaps, use any appeal-driven rally to initiate or add a tightly sized GAUZ short over the next 1-3 months; target is a return toward OTC/liquidation-value pricing, with a hard stop on disclosure of committed financing or a strategic transaction.
• Do not short solely on a sub-$1 price move if borrow is punitive or unavailable. Set an alert for a reverse-split announcement or equity-linked financing, where post-event liquidity may improve and the dilution mechanism becomes quantifiable.
• Treat a filed audited 20-F with at least 12 months of funded runway, plus a favorable Nasdaq panel decision, as the key invalidation trigger; cover shorts or stand aside if both occur before a dilutive capital raise.